J. Wong

Prostate brachytherapy biochemical relapse-free survival outcomes in intermediate-risk prostate cancer patients

J. Sylvester, P. Grimm, G. Merrick, 2009 .

Randomized trial comparing intra-operative flexible, regid and no cystoscopy after prostate brachytherapy

J. Sylvester, P. Grimm, Erik Torgerson, 2009 .

The use of RapidArc volumetric-modulated arc therapy to deliver stereotactic radiosurgery and stereotactic body radiotherapy to intracranial and extracranial targets.

J. Kuo, M. Al-Ghazi, Juying Zhang, 2012, Medical dosimetry : official journal of the American Association of Medical Dosimetrists.

Fifteen-year biochemical relapse-free survival, cause-specific survival, and overall survival following I(125) prostate brachytherapy in clinically localized prostate cancer: Seattle experience.

J. Blasko, J. Sylvester, P. Grimm, 2011, International journal of radiation oncology, biology, physics.

Comparative analysis of prostate‐specific antigen free survival outcomes for patients with low, intermediate and high risk prostate cancer treatment by radical therapy. Results from the Prostate Cancer Results Study Group

Adam P Dicker, Richard Stock, Steven Frank, 2012, BJU international.

First report on the use of a thinner (125)I radioactive seed within 20-gauge needles for permanent radioactive seed prostate brachytherapy: evaluation of postimplant dosimetry and acute toxicity.

J. Sylvester, P. Grimm, Devi Naidoo, 2009, Brachytherapy.

Familial colorectal cancer risk by subsite of primary cancer: a population‐based study in Utah

K. Smith, D. Ahnen, N. Samadder, 2015, Alimentary pharmacology & therapeutics.